title: Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial.
abstract: Tazarotene 0.1% gel and tretinoin 0.025% gel are both effective in the treatment of acne vulgaris. Results of a multicenter, double-blind, randomized, parallel-group study that compared the efficacy and tolerability of these drugs are presented here. A total of 143 patients with mild-to-moderate facial acne vulgaris were randomized to receive tazarotene 0.1% gel or tretinoin 0.025% gel once daily for 12 weeks. Tazarotene 0.1% gel was more effective than tretinoin 0.025% gel in reducing the open comedo count (P < or = .05), the total noninflammatory lesion count (P < or = .05), and the total inflammatory lesion count (not statistically significant). At some time points, tazarotene was associated with increased irritation, but peeling, erythema, dryness, burning, and itching never exceeded trace levels. We conclude that tazarotene 0.1% gel is more effective than tretinoin 0.025% gel in reducing noninflammatory lesions and similarly effective in reducing inflammatory lesions.
authors.affiliation: Jefferson Medical College, Philadelphia, Pennsylvania, USA.
authors.forename: G F
authors.initials: GF
authors.lastname: Webster
authors.forename: D
authors.initials: D
authors.lastname: Berson
authors.forename: L F
authors.initials: LF
authors.lastname: Stein
authors.forename: D P
authors.initials: DP
authors.lastname: Fivenson
authors.forename: E A
authors.initials: EA
authors.lastname: Tanghetti
authors.forename: M
authors.initials: M
authors.lastname: Ling
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012176:Retinoids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D005782:Gels; D007641:Keratolytic Agents; D009539:Nicotinic Acids; D012176:Retinoids; D014212:Tretinoin; C086827:tazarotene